The estimated Net Worth of Cedric Francois is at least $31.6 Million dollars as of 1 March 2024. Cedric Francois owns over 250,000 units of Apellis Pharmaceuticals Inc stock worth over $21,622,074 and over the last 5 years he sold APLS stock worth over $5,678,661. In addition, he makes $4,267,180 as President, Chief Executive Officer, Co-Founder und Director at Apellis Pharmaceuticals Inc.
Cedric has made over 36 trades of the Apellis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 250,000 units of APLS stock worth $1,050,000 on 1 March 2024.
The largest trade he's ever made was exercising 300,000 units of Apellis Pharmaceuticals Inc stock on 1 September 2023 worth over $801,000. On average, Cedric trades about 33,190 units every 34 days since 2019. As of 1 March 2024 he still owns at least 563,662 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Cedric Francois stock trades at the bottom of the page.
Dr. Cedric Francois M.D. Ph.D. serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015. Dr. Francois serves on the board of directors of Liberate Medical, Inc., a private medical device company, and, until July 2019, served on the board of directors of Revon Systems, Inc., or Revon, a private healthcare software company which he cofounded. Dr. Francois served as President and Chief Executive Officer of Potentia from 2001 to 2018. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France. Francois is qualified to serve on our board of directors because of his expertise and extensive leadership experience in immunology and immune system-mediated diseases and his extensive knowledge of our company based on his role as co-founder and Chief Executive Officer.
As the President, Chief Executive Officer, Co-Founder und Director of Apellis Pharmaceuticals Inc, the total compensation of Cedric Francois at Apellis Pharmaceuticals Inc is $4,267,180. There are no executives at Apellis Pharmaceuticals Inc getting paid more.
Cedric Francois is 47, he's been the President, Chief Executive Officer, Co-Founder und Director of Apellis Pharmaceuticals Inc since 2016. There are 16 older and 4 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
Cedric's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois und Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: